Mesothelioma Included in Department of Defense Spending Bill

cdmrp_logoEarlier this month, the House Appropriations Committee passed the FY2014 Defense Appropriations Bill, which included mesothelioma as a topic area in their Peer Reviewed Cancer Research Program for the third year.  Mesothelioma researchers will be eligible to apply for $15 million in research funding.

Mesothelioma has been included on the list of diseases eligible to receive funding through the Department of Defense’s Congressionally Directed Medical Research Program (CDMRP) since Fiscal Year 2008. The CDMRP has funded a total of $8.9 million in mesothelioma research to date. In Fiscal Years 2008, 2009, and 2010 it was included in the Peer Reviewed Medical Research Program (PRMRP) to compete for $50 million dollars.

In 2011, due to the advocacy of the mesothelioma community, it was moved to the Peer Reviewed Cancer Research Program (PRCRP), to compete with a smaller number of topic areas for $16 million.  In 2012, this sparse amount of funding was decreased to $12.8 million. It returned to $16 million in 2013. The $15 million included in the House Defense Bill is slightly more than a 6% cut from the 2013 amount.

“We are pleased that the advocacy of the mesothelioma community has continued to secure this funding for mesothelioma for the 7th consecutive year,” said the executive director of the Mesothelioma Applied Research Foundation, Mary Hesdorffer, Nurse Practitioner.  “We commend Congress for recognizing the increased risk of developing mesothelioma for our service men and women and continuing to fund this much needed research.”

This bill will next move to the House Floor, and then on to the Senate. The Meso Foundation will continue to follow the appropriations process, so stay tuned for more information.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>